Hercules Capital (HTGC) gained 1.16% to $16.55, outperforming the S&P 500's 0.47% decline on October 8, 2026. However, the stock has declined 7.1% over the past month. Analysts expect Q3 EPS of $0.49 (flat year-over-year) and revenue of $142.2 million (+2.98% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 8.39, trading at a premium to its industry average of 7.28.

Hercules Capital (HTGC) closed at $16.74, down 1.18%, underperforming the S&P 500's 0.73% gain. The stock has declined 4.4% over the past month. The company is expected to report unchanged EPS of $0.49 with projected revenue growth of 2.98% year-over-year. For the full year, earnings are forecast to grow 2.09% to $1.95 per share. HTGC holds a Zacks Rank #3 (Hold) with a Forward P/E of 8.69, trading at a premium to its industry average of 7.49.

Hercules Capital (HTGC) closed down 1.45% and underperformed the S&P 500. The specialty finance company is expected to post steady EPS of $0.49 with revenue growth of 2.98% year-over-year. For fiscal year 2026, earnings are projected to grow 2.09% to $1.95 per share with revenue increasing 8.56% to $578.1 million. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 8.83, trading at a premium to its industry average of 7.98.

Hercules Capital (HTGC) declined 1.25% on September 10, 2026, outpacing the broader market's 0.59% loss. Despite a 6.08% monthly gain, the stock faces flat earnings expectations with no growth projected year-over-year. The company holds a Zacks Rank #3 (Hold) rating and trades at a Forward P/E of 9.03, above its industry average of 8.12.

While Wall Street analysts maintain an optimistic view of Hercules Capital with an average brokerage recommendation of 1.50 (Strong Buy/Buy), the article cautions that brokerage recommendations often have a positive bias and may not reliably predict stock performance. The Zacks Rank system rates HTGC as a #3 (Hold), citing unchanged earnings estimates of $1.95 for the current year, suggesting the stock may perform in line with the broader market in the near term.

4D Molecular Therapeutics (FDMT) announced a strategic credit facility agreement with Hercules Capital (HTGC) for up to $200 million in non-dilutive financing. The company drew an initial $20 million at closing, with additional tranches available through 2027 and upon achievement of certain milestones. This financing strengthens 4DMT's cash position of $458 million as of March 31, 2026, and provides operational flexibility as the company advances its lead product 4D-150 through Phase 3 development for wet AMD and DME.

Pomerantz Law Firm has filed a class action lawsuit against Hercules Capital, Inc. following a Hunterbrook Media short report alleging securities fraud and improper business practices. The report claimed the company copied investment strategies from Google Ventures, lacked adequate due diligence processes, had an understaffed valuation team with insufficient oversight, and misrepresented software debt exposure. Hercules' stock fell 7.91% to $14.21 per share following the report publication on February 27, 2026.

A class action lawsuit has been filed against Hercules Capital, Inc. (HTGC) following allegations that the company misrepresented its deal sourcing and portfolio valuation processes. According to a Hunterbrook Media report citing former employees, Hercules Capital allegedly copied investment strategies from Google Ventures without conducting independent due diligence and maintained an understaffed valuation team with inadequate oversight. The company also allegedly misclassified software investments and overstated book values. The stock fell 7.9% on the news. Investors who purchased HTGC securities between May 1, 2025 and February 27, 2026 can file a lead plaintiff motion by May 19, 2026.

A class action lawsuit has been filed against Hercules Capital, Inc. (NYSE: HTGC) alleging that the company made materially false statements and failed to disclose material facts about its business operations. The complaint specifically alleges that Hercules overstated due diligence in its deal sourcing, loan origination, and portfolio valuation processes, and misclassified portfolio investments. Investors who purchased Hercules securities between May 1, 2025 and February 27, 2026 are encouraged to join the lawsuit, with a lead plaintiff deadline of May 19, 2026.

Rosen Law Firm is urging investors in Hercules Capital, Inc. who suffered losses exceeding $100,000 to seek legal counsel before the May 19, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Hercules Capital made false statements regarding its due diligence processes, portfolio valuations, and investment classifications, resulting in materially misleading statements about the company's business and operations.

A class action lawsuit has been filed against Hercules Capital, Inc. alleging that the company made materially false statements and failed to disclose material facts about its business operations. The complaint specifically alleges that Hercules overstated due diligence in its deal sourcing, loan origination, and portfolio valuation processes, and misclassified portfolio investments. The class period covers purchases between May 1, 2025 and February 27, 2026, with a lead plaintiff deadline of May 19, 2026.

A securities class action lawsuit has been filed against Hercules Capital, Inc. (HTGC) alleging the company made false and misleading statements regarding its due diligence processes, portfolio valuations, and investment classifications. Investors who purchased HTGC securities between May 1, 2025 and February 27, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is May 19, 2026.